TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02630108

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermal Ablation
Description: Thermal ablation in this trial includes radiofrequency ablation and microwave ablation, one of them can be chosen to be performed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EADM
Description: EADM is a chemotherapy drug used in transarterial chemoembolization (TACE).Dosage: EADM 30-60 mg per patient,depending on the situation of the patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EADM
Description: EADM is a chemotherapy drug used in transarterial chemoembolization (TACE).Dosage: EADM 30-60 mg per patient,depending on the situation of the patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultra-fluid lipiodol
Description: Ultra-fluid lipiodol is a kind of embolization material used in TACE. Standard: 38% ultra-fluid lipiodol .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultra-fluid lipiodol
Description: Ultra-fluid lipiodol is a kind of embolization material used in TACE. Standard: 38% ultra-fluid lipiodol .

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin sponge articles
Description: Gelatin sponge articles embolization material used in TACE. Standard: 350-560 um in diameter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gelatin sponge articles
Description: Gelatin sponge articles embolization material used in TACE. Standard: 350-560 um in diameter.
Study: NCT00197587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine
Description: All women received a background of zidovudine from 34 weeks' gestation through delivery, and all infants received single-dose nevirapine at birth and zidovudine from birth through 1 month. Women were randomized to receive either single-dose nevirapine or placebo during labor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: All women received a background of zidovudine from 34 weeks'gestation through delivery, and all infants received single-dose nevirapine at birth and zidovudine from birth through 1 month. Women were randomized to receive either single-dose nevirapine or placebo during labor.
Study: NCT00603304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saw Palmetto - first 24 weeks
Description: Participants will take one 320 mg chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - first 24 weeks
Description: Participants will take one 320 mg chocolate-colored soft gelcaps containing a placebo for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saw Palmetto - weeks 24 - 48
Description: Participants will take 640 mg (2) chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - weeks 24 - 48
Description: Participants will take 640 mg (2) chocolate-colored soft gelcaps containing a placebo for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saw Palmetto - weeks 48 - 72
Description: Participants will take 960 (3) mg chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - weeks 48 - 72
Description: Participants will take 960 (3) mg chocolate-colored soft gelcaps containing a placebo for 24 weeks.
Study: NCT03368729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib is an oral PARP-1 and -2 inhibitor with high potency.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib is an oral PARP-1 and -2 inhibitor with high potency.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib is an oral PARP-1 and -2 inhibitor with high potency.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab is a commercially available agent administered by intravenous infusion. A loading dose of 8 mg/kg will be given as the first dose followed with all subsequent doses of 6 mg/kg every 3 weeks.
Study: NCT02699164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: electrotherapy was used. electrotherapy consisted of 20 minutes of hot-pack, 20 minutes of TENS and 5 minutes of ultrasound.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: electrotherapy was used. electrotherapy consisted of 20 minutes of hot-pack, 20 minutes of TENS and 5 minutes of ultrasound.
Study: NCT03368729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab is a commercially available agent administered by intravenous infusion. A loading dose of 8 mg/kg will be given as the first dose followed with all subsequent doses of 6 mg/kg every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab is a commercially available agent administered by intravenous infusion. A loading dose of 8 mg/kg will be given as the first dose followed with all subsequent doses of 6 mg/kg every 3 weeks.
Study: NCT01129544

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gene transfer
Description: Three procedures: 1) Bone marrow harvest from the patient's posterior iliac crests. 2.) Chemotherapy conditioning with Busulfan 3)One time infusion of patient's transduced bone marrow cells.
Study: NCT01533597

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin
Description: Solifenacin (5mg, qd, oral)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin plus Tamsulosin
Description: Solifenacin (5mg, qd, oral) plus Tamsulosin (0.2mg, qd, oral)
Study: NCT00249054

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ASR hip prosthesis
Description: Implantation of resurfacing prosthesis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReCap hip prosthesis
Description: Implantation of resurfacing prosthesis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReCap hip prosthesis
Description: Implantation of resurfacing prosthesis
Study: NCT04865198

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurl1 gene expression
Description: This observational case control study. The gene expression was examined.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurl1 gene expression
Description: This observational case control study. The gene expression was examined.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurl1 gene expression
Description: This observational case control study. The gene expression was examined.

Intervention type: DIAGNOSTIC_TEST
Intervention: RGS14 gene expression
Description: This observational case control study. The gene expression was examined.

Intervention type: DIAGNOSTIC_TEST
Intervention: RGS14 gene expression
Description: This observational case control study. The gene expression was examined.

Intervention type: DIAGNOSTIC_TEST
Intervention: RGS14 gene expression
Description: This observational case control study. The gene expression was examined.
Study: NCT02275000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 Day Physiotherapy Programme
Description: The experimental group will complete a 5 day physiotherapy programme consisting of education, movement retraining and a self management plan.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Treatment as usual physiotherapy. The participant will be referred to their closest NHS outpatient neuro-physiotherapy service.
Study: NCT00670631

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: tandem autologous transplantation
Description: DPACE: dexamethasone 20 mg days 1-4 and 8-11, cisplatin 10 mg/m2 days 1-4, Adriamycin 10 mg/m2 days 1-4, cyclophosphamide 400 mg/m2 days 1-4, etoposide 40 mg/m2 days 1-4.~Transplant 1: Dexamethasone 20 mg days -4 to -1 and +2 to +5. Velcade 1mg/m2 on days -4,-1, +2, and +5. Thalidomide 100mg on day -4 to day +5. Melphalan, 100 mg/m2 on days -4 and -1.~Transplant 2: Dexamethasone 20 mg on days -4 to -1 and +2 to +5. BCNU 300mg/m2 on day -4. Melphalan 140 mg/m2 on day -1. Velcade 1mg/m2 on days -4, -1, +2, +5. Gemcitabine 1000 mg/m2 on days -4 + -1.~Maintenance year 1: Bortezomib 1.0 mg/m2 on days 1, 4, 15,18 every cycle. Thalidomide, 100 mg . Dexamethasone,20 mg,on days 1-4 \& 15-18 every cycle.~Maintenance year 2: Dexamethasone, 20 mg,days 1-4 every cycle.
Study: NCT00194987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG (Intravenous Immunoglobulin)
Description: one gram per kg of IVIG per infusion given either once or twice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG (Intravenous Immunoglobulin)
Description: one gram per kg of IVIG per infusion given either once or twice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: in arm with IVIG 1 gm/kg/wk will also receive prednisone 0.5 mg/kg/day
Study: NCT01505218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol sedation by nurse anaesthestist
Description: Propofol (10 mg/ml) is a short-acting, intravenously administered hypnotic agent used for light-moderate-deep sedation.~Patient-controlled sedation: self-administration of propofol boluses of 5 mg with zero lock-out time. Administration time for the pump was 12 sec, equivalent to maximum delivery of 25 mg of propofol per minute.~Propofol sedation by nurse anaesthetists:

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled propofol sedation
Description: Propofol (10 mg/ml) is a short-acting, intravenously administered hypnotic agent used for light-moderate-deep sedation.~Self-administration of propofol via patient-controlled sedation pump (CME T-34L PCA). No programmed lock-out period, no dose limit or background infusion. 5 mg propofol/effectuated demand from the patients. Capacity of the pump was 6 possible doses per minute.~Before start of ERCP the patients were allowed to sedate themselves to a sense of heavy tiredness.
Study: NCT00070824

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Study: NCT02551718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemosensitivity Assay
Description: Lab test in which leukemia cells obtained from blood or bone marrow are tested for sensitivity to 115 drugs individually and in certain combinations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Undergo blood or bone marrow collection

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Gene Expression Analysis
Description: Analysis of leukemia cell genes to identify possible drug targets

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic Variation Analysis
Description: Analysis of leukemia cell genes to identify possible drug targets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: In Vitro Sensitivity-Directed Chemotherapy
Description: Receive personalized chemotherapy with one or more of the following drugs:~Afatinib Arsenic trioxide Axitinib Azacitidine Bexarotene Bortezomib Bosutinib Busulfan Cabazitaxel Cabozantinib Carfilzomib Ceritinib Cladribine Clofarabine Crizotinib Cytarabine HCl Dabrafenib Dasatinib Daunorubicin HCl Decitabine Erlotinib Etoposide Everolimus Fludarabine Gefitinib Gemcitabine HCl Hydroxyurea Imatinib Irinotecan Lapatinib Lomustine Melphalan Mercaptopurine Methotrexate Mitoxantrone Nelarabine Nilotinib Paclitaxel Pazopanib Pentostatin Ponatinib Pralatrexate Rapamycin Regorafenib Romidepsin Ruxolitinib Sorafenib Sunitinib Temsirolimus Thioguanine Topotecan HCl Trametinib Tretinoin
Study: NCT00688883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate (Fludara)
Description: Patients received Fludarabine Phosphate orally for 5 consecutive days, followed by a 23-day observation period. Setting this as 1 treatment cycle, 6 cycles will be given.
Study: NCT00513968

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir
Description: Adefovir(Adefovir dipivoxil)10mg, od, from week -10 to week 48.
Study: NCT00635154

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anakinra (IL-1Ra)
Description: 100mg daily subcutaneously administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone acetate
Description: Low dose - 20 mg/week~High dose - 40mg days 1-4, 9-12, 17-20 every 28 days ODD cycles OR 40 mg days 1-4 every 28 days EVEN cycles. (Starting dose was determined by treating physician)
Study: NCT02422017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol
Description: Patients will receive one drop of timolol every 6cm ² every other day for twelve weeks applied on the ulcer of interest

Intervention type: OTHER
Group type: OTHER
Intervention: Local care treatment
Description: Local care treatment with dressing compression in accordance with standards applied every other day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local care treatment
Description: Local care treatment with dressing compression in accordance with standards applied every other day
Study: NCT01814852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave system

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Sham treatment that looks, sounds and feels like real LI-ESWT treatment by Renova.
Study: NCT00717431

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Hippocampal Electrical Stimulation
Description: Surgical Implantation of electrode and stimulator

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hippocampal Electrical Stimulation
Description: Surgical Implantation of electrode and stimulator
Study: NCT02342431

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Forced air warming compressible
Description: Warming with a compressible forced air mattress

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forced air non-compressible
Description: Warming with a non-compressible forced air mattress
Study: NCT01693705

Intervention type: PROCEDURE
Intervention: Tracheostomy
Study: NCT03051789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Menstrual Cup
Description: Menstrual cups are reusable bell-shaped receptacles made of high grade medical silicone which collect \~30 ml of menstrual blood when inserted into the vaginal canal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash transfer
Description: A small stipend of Ksh 1500 (US$15, Dec15 exch) per term will be provided to girls, through a safe and secure mobile money transfer system provider, like M-Pesa, Equity, or Postbank. Monies will be transferred at the beginning of a term, based on school registry statistics confirming participants attended for at least 80% of the previous term.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cups and Cash
Description: Combination of both interventions, using the same interventions and implementation methods.
Study: NCT04288375

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Description: The prescribed dose of radiations for all patients will be 50 Gy in 25 fractions. 6MV energy photons will be used. Multi-beam IMRT plans, utilizing dynamic multileaf collimation, will be created based on the target tissue coverage and normal tissue avoidance.
Study: NCT03689959

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eight plate hemiepiphysiodesis
Description: Patient is positioned in a classic supine position. Under fluoroscopic guidance and tourniquet hemostasis, the distal femoral physis is identified. Two 3-cm incisions are made, one on either side of the patella, centred at the level of the physis. The capsule and synovium are opened to visualize the sulcus and place the plates just outside the articular portion of the joint surface, medially and laterally. Care is taken not to damage the periosteum and a needle is inserted into the physis. The 8-plate, which has a central hole, is slipped over the needle and screws inserted. After wound closure, a soft dressing is used, and the patient is allowed to ambulate as tolerated.
Study: NCT03483259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfatinib T capsule
Description: Sulfatinib T capsules were produced by Hutchison Whampoa Pharmaceutical (Suzhou) Co., Ltd. production.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfatinib R capsule
Description: Sulfatinib R capsules were produced by Beijing Yiling Bioengineering Technology Co., Ltd.
Study: NCT04109105

Intervention type: OTHER
Intervention: NHS-PEG coated collagen patch
Description: Analysis of the number and seriousness of leaks in the ileocolic anastomosis after using a NHS-PEG coated collagen patch reinforcement.
Study: NCT03775395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: 400mg BID daily oral dosing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy
Description: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepatic arterial infusion chemotherapy
Description: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
Study: NCT03112057

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: harmonic generation (HGM) microscopic methods.
Description: a frequency-dependent optical microscopy system with a near-infrared light source with a wavelength of 1230 nm was used to detect the diseased site and normal skin.Use erbium-Jacob (Er-YAG) laser exfoliation. the participants need to lie down, wear goggles. The lens sucker device to help fix the skin examination site. Based on the experience of the past 118 subjects, the participants did not discomfort. The total time of the laser irradiation on the same skin is no more than 30 minutes, the maximum laser power is no more than 0.15 watts, irradiation in the skin of the total energy of the laser does not exceed 270 joules. After the experiment, the investigators immediately check the skin for the participants

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: harmonic generation (HGM) microscopic methods.
Description: a frequency-dependent optical microscopy system with a near-infrared light source with a wavelength of 1230 nm was used to detect the diseased site and normal skin.Use erbium-Jacob (Er-YAG) laser exfoliation. the participants need to lie down, wear goggles. The lens sucker device to help fix the skin examination site. Based on the experience of the past 118 subjects, the participants did not discomfort. The total time of the laser irradiation on the same skin is no more than 30 minutes, the maximum laser power is no more than 0.15 watts, irradiation in the skin of the total energy of the laser does not exceed 270 joules. After the experiment, the investigators immediately check the skin for the participants

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: harmonic generation (HGM) microscopic methods.
Description: a frequency-dependent optical microscopy system with a near-infrared light source with a wavelength of 1230 nm was used to detect the diseased site and normal skin.Use erbium-Jacob (Er-YAG) laser exfoliation. the participants need to lie down, wear goggles. The lens sucker device to help fix the skin examination site. Based on the experience of the past 118 subjects, the participants did not discomfort. The total time of the laser irradiation on the same skin is no more than 30 minutes, the maximum laser power is no more than 0.15 watts, irradiation in the skin of the total energy of the laser does not exceed 270 joules. After the experiment, the investigators immediately check the skin for the participants
Study: NCT04277351

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation
Description: Focal transcranial stimulation over auditory cortex by means of 5 electrodes delivering an electric current (max. 2mA). In addition to active stimulation, also a placebo (sham) stimulation is employed as a control condition. All subjects included in the study receive all tACS stimulation conditions.
Study: NCT03112057

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: harmonic generation (HGM) microscopic methods.
Description: a frequency-dependent optical microscopy system with a near-infrared light source with a wavelength of 1230 nm was used to detect the diseased site and normal skin.Use erbium-Jacob (Er-YAG) laser exfoliation. the participants need to lie down, wear goggles. The lens sucker device to help fix the skin examination site. Based on the experience of the past 118 subjects, the participants did not discomfort. The total time of the laser irradiation on the same skin is no more than 30 minutes, the maximum laser power is no more than 0.15 watts, irradiation in the skin of the total energy of the laser does not exceed 270 joules. After the experiment, the investigators immediately check the skin for the participants

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: harmonic generation (HGM) microscopic methods.
Description: a frequency-dependent optical microscopy system with a near-infrared light source with a wavelength of 1230 nm was used to detect the diseased site and normal skin.Use erbium-Jacob (Er-YAG) laser exfoliation. the participants need to lie down, wear goggles. The lens sucker device to help fix the skin examination site. Based on the experience of the past 118 subjects, the participants did not discomfort. The total time of the laser irradiation on the same skin is no more than 30 minutes, the maximum laser power is no more than 0.15 watts, irradiation in the skin of the total energy of the laser does not exceed 270 joules. After the experiment, the investigators immediately check the skin for the participants
Study: NCT00648518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride ER Tablets 750 mg
Description: 750mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage® XR Tablets 750 mg
Description: 750mg, single dose fasting
Study: NCT01493479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y Ibritumomab tiuxetan
Description: 2 x iv infusions of 11.1 MBq/kg. 1st infusion at week 1, 2nd during weeks 9-13. 2nd infusion may be reduced to 7.4MBq/kg in the case of grade 3 haematological toxicity following the 1st infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: All patients receive 2 x iv infusions of 250 mg/m2 Rituximab given 7-8 days apart prior to each zevalin infusion. The 2nd rituximab infusion is given immediately prior to Zevalin.~In addition patients with greater than 20% bone marrow involvement at screening receive rituximab pretreatment prior to entering the main treatment phase of the trial, consisting of 4 x weekly iv doses of rituximab(375 mg/m2). This is followed by a repeat bone marrow biopsy, bone marrow involvement must have fallen to \<= 20% to enter the main treatment phase of the trial.